Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Cash from Operations of 88840000.0 for Q1 2026, down 12.24% year-over-year from 101233602.07 in Q1 2025, and down 33.1% quarter-over-quarter from 66747000.0 in Q4 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Cash from Operations for 8 consecutive years, with 88840000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 12.24% year-over-year to 88840000.0; the TTM figure through Mar 2026 stood at 242581000.0 (down 3.64% YoY), while the FY2025 annual figure was 232891000.0, down 19.74% from the prior year.
- Cash from Operations slipped to 88840000.0 in Q1 2026 per KYMR's latest filing, from 66747000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8045000.0 in Q4 2023 and bottomed at 88840000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 45420176.47 across 5 years, with a median of 40295000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 120.35% — and 2024, when it tumbled 867.98%.
- Kymera Therapeutics' Cash from Operations stood at 39536000.0 in 2022, then surged by 120.35% to 8045000.0 in 2023, then sank by 867.98% to 61784000.0 in 2024, then dropped by 8.03% to 66747000.0 in 2025, then tumbled by 33.1% to 88840000.0 in 2026.
- Business Quant data shows KYMR's Cash from Operations at 88840000.0 in Q1 2026, 66747000.0 in Q4 2025, and 27110000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | -54.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54.07 Mn |
| Mar 31, 2026 | -88.84 Mn |
| Dec 31, 2025 | -66.75 Mn |
| Sep 30, 2025 | -27.11 Mn |
| Jun 30, 2025 | -59.88 Mn |
| Mar 31, 2025 | -79.15 Mn |
| Dec 31, 2024 | -61.78 Mn |
| Sep 30, 2024 | -50.19 Mn |
| Jun 30, 2024 | -42.94 Mn |
| Mar 31, 2024 | -39.59 Mn |
| Dec 31, 2023 | 8.05 Mn |
| Sep 30, 2023 | -31.65 Mn |
| Jun 30, 2023 | -35.26 Mn |
| Mar 31, 2023 | -43.97 Mn |
| Dec 31, 2022 | -39.54 Mn |
| Sep 30, 2022 | -34.27 Mn |
| Jun 30, 2022 | -38.99 Mn |
| Mar 31, 2022 | -40.30 Mn |
| Dec 31, 2021 | -38.35 Mn |
| Sep 30, 2021 | -37.26 Mn |